Your browser doesn't support javascript.
loading
Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.
Porrello, Alessandro; Leslie, Patrick L; Harrison, Emily B; Gorentla, Balachandra K; Kattula, Sravya; Ghosh, Subrata K; Azam, Salma H; Holtzhausen, Alisha; Chao, Yvonne L; Hayward, Michele C; Waugh, Trent A; Bae, Sanggyu; Godfrey, Virginia; Randell, Scott H; Oderup, Cecilia; Makowski, Liza; Weiss, Jared; Wilkerson, Matthew D; Hayes, D Neil; Earp, H Shelton; Baldwin, Albert S; Wolberg, Alisa S; Pecot, Chad V.
Afiliación
  • Porrello A; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Leslie PL; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Harrison EB; Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Gorentla BK; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Kattula S; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Ghosh SK; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Azam SH; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Holtzhausen A; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Chao YL; Division of Hematology & Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Hayward MC; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Waugh TA; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Bae S; Division of Hematology & Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Godfrey V; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Randell SH; Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Oderup C; Marsico Lung Institute/Cystic Fibrosis Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Makowski L; Cancer Immunology, Pfizer, Inc, San Francisco, CA, 94080, USA.
  • Weiss J; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Wilkerson MD; Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Hayes DN; Nutrition Obesity Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Earp HS; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Baldwin AS; Division of Hematology & Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Wolberg AS; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Pecot CV; Department of Anatomy, Physiology and Genetics, The American Genome Center, Collaborative Health Initiative Research Program, Uniformed Services University, Bethesda, MD, 20814, USA.
Nat Commun ; 9(1): 1988, 2018 05 18.
Article en En | MEDLINE | ID: mdl-29777108
ABSTRACT
Lung cancer is the leading cause of cancer-related deaths worldwide, and lung squamous carcinomas (LUSC) represent about 30% of cases. Molecular aberrations in lung adenocarcinomas have allowed for effective targeted treatments, but corresponding therapeutic advances in LUSC have not materialized. However, immune checkpoint inhibitors in sub-populations of LUSC patients have led to exciting responses. Using computational analyses of The Cancer Genome Atlas, we identified a subset of LUSC tumors characterized by dense infiltration of inflammatory monocytes (IMs) and poor survival. With novel, immunocompetent metastasis models, we demonstrated that tumor cell derived CCL2-mediated recruitment of IMs is necessary and sufficient for LUSC metastasis. Pharmacologic inhibition of IM recruitment had substantial anti-metastatic effects. Notably, we show that IMs highly express Factor XIIIA, which promotes fibrin cross-linking to create a scaffold for LUSC cell invasion and metastases. Consistently, human LUSC samples containing extensive cross-linked fibrin in the microenvironment correlated with poor survival.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrina / Carcinoma de Células Escamosas / Monocitos / Factor XIIIa / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrina / Carcinoma de Células Escamosas / Monocitos / Factor XIIIa / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos